Total Payments
$1.4M
2024 Payments
$172,911
Companies
49
Transactions
434
Medicare Patients
4,411
Medicare Billing
$959,196
Payment Breakdown by Category
Other$1.1M (77.4%)
Consulting$226,222 (16.5%)
Research$57,133 (4.2%)
Food & Beverage$12,464 (0.9%)
Travel$7,581 (0.6%)
Education$7,015 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Grant | $622,035 | 20 | 45.4% |
| Honoraria | $264,651 | 4 | 19.3% |
| Consulting Fee | $226,222 | 71 | 16.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $169,045 | 14 | 12.3% |
| Unspecified | $57,133 | 11 | 4.2% |
| Food and Beverage | $12,464 | 281 | 0.9% |
| Travel and Lodging | $7,581 | 29 | 0.6% |
| Education | $7,015 | 2 | 0.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,610 | 1 | 0.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $1,800 | 1 | 0.1% |
Payments by Type
General
$1.3M
423 transactions
Research
$57,133
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $332,610 | 36 | $0 (2024) |
| Galderma Laboratories, L.P. | $310,121 | 55 | $0 (2022) |
| Sensus Healthcare, Inc. | $271,039 | 14 | $0 (2020) |
| Lumenis, Inc | $145,485 | 4 | $0 (2020) |
| Musculoskeletal Transplant Foundation Inc. | $125,011 | 19 | $0 (2024) |
| Allergan, Inc. | $83,517 | 84 | $0 (2022) |
| Ra Medical Systems, Inc. | $15,116 | 1 | $0 (2018) |
| MERZ NORTH AMERICA, INC. | $12,886 | 26 | $0 (2021) |
| Biofrontera Inc. | $12,152 | 13 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $10,250 | 8 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $172,911 | 41 | ABBVIE INC. ($143,723) |
| 2023 | $219,433 | 40 | ABBVIE INC. ($188,887) |
| 2022 | $39,250 | 52 | Musculoskeletal Transplant Foundation Inc. ($25,620) |
| 2021 | $69,408 | 45 | Musculoskeletal Transplant Foundation Inc. ($57,088) |
| 2020 | $88,166 | 21 | Galderma Laboratories, L.P. ($45,264) |
| 2019 | $198,558 | 70 | Galderma Laboratories, L.P. ($71,601) |
| 2018 | $282,778 | 69 | Galderma Laboratories, L.P. ($134,872) |
| 2017 | $300,055 | 96 | Sensus Healthcare, Inc. ($108,782) |
All Payment Transactions
434 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Winlevi (Drug) | Food and Beverage | In-kind items and services | $21.67 | General |
| Category: Dermatology | ||||||
| 11/27/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $15.69 | General |
| Category: Immunology | ||||||
| 11/22/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $16.14 | General |
| Category: Dermatology | ||||||
| 11/15/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $338.00 | General |
| 11/13/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $16.83 | General |
| Category: Inflammation | ||||||
| 11/05/2024 | Fidia Pharma USA Inc. | — | Food and Beverage | In-kind items and services | $20.37 | General |
| 10/31/2024 | ABBVIE INC. | SKYRIZI (Biological) | Grant | Cash or cash equivalent | $7,500.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/17/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $12.68 | General |
| 10/15/2024 | ABBVIE INC. | — | Grant | Cash or cash equivalent | $45,000.00 | General |
| 09/11/2024 | Musculoskeletal Transplant Foundation Inc. | — | Consulting Fee | Cash or cash equivalent | $3,500.00 | General |
| 08/28/2024 | Verrica Pharmaceuticals Inc. | YCANTH (Drug) | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| Category: DERMATOLOGY | ||||||
| 08/16/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $109.92 | General |
| Category: FACIAL AESTHETICS | ||||||
| 08/16/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $42.32 | General |
| 08/15/2024 | Biofrontera Inc. | BF-RhodoLED (Device), Ameluz, RhodoLED XL | Consulting Fee | Cash or cash equivalent | $7,500.00 | General |
| Category: Dermatology | ||||||
| 08/14/2024 | Verrica Pharmaceuticals Inc. | YCANTH (Drug) | Consulting Fee | Cash or cash equivalent | $5,250.00 | General |
| Category: DERMATOLOGY | ||||||
| 07/23/2024 | ABBVIE INC. | — | Grant | Cash or cash equivalent | $87,250.00 | General |
| 07/18/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Food and Beverage | In-kind items and services | $17.17 | General |
| Category: Immunology | ||||||
| 07/12/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | — | Food and Beverage | In-kind items and services | $27.96 | General |
| 06/12/2024 | Musculoskeletal Transplant Foundation Inc. | — | Consulting Fee | Cash or cash equivalent | $4,200.00 | General |
| 06/12/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| 05/16/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $150.00 | General |
| 05/14/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $16.06 | General |
| Category: Dermatology | ||||||
| 04/26/2024 | ABBVIE INC. | BOTOX (Biological) | — | In-kind items and services | $676.21 | Research |
| Study: BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study • Category: FACIAL AESTHETICS | ||||||
| 04/26/2024 | ABBVIE INC. | BOTOX (Biological) | — | In-kind items and services | $111.18 | Research |
| Study: BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study • Category: FACIAL AESTHETICS | ||||||
| 04/25/2024 | ABBVIE INC. | — | — | In-kind items and services | $375.00 | Research |
| Study: BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Evaluating the effects of renuvaHD treatment on human skin quality and nasolabial fold volume restoration. | Musculoskeletal Transplant Foundation Inc. | $30,000 | 2 |
| Evaluating the effects of renuvahd treatment on human skin quality and nasolabial fold volume restoration | Musculoskeletal Transplant Foundation Inc. | $20,420 | 1 |
| Keloid Scar Study Completion of Data collection | Sensus Healthcare, Inc. | $3,000 | 1 |
| Keloid Scar Study | Sensus Healthcare, Inc. | $2,000 | 1 |
| BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study | ABBVIE INC. | $1,669 | 5 |
| A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence | ABBVIE INC. | $44.47 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 1,048 | 1,612 | $684,830 | $227,427 |
| 2022 | 18 | 880 | 1,322 | $659,810 | $220,953 |
| 2021 | 23 | 1,096 | 1,650 | $802,751 | $267,687 |
| 2020 | 24 | 1,387 | 2,214 | $693,526 | $243,129 |
Total Patients
4,411
Total Services
6,798
Medicare Billing
$959,196
Procedure Codes
84
All Medicare Procedures & Services
84 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 17311 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | Office | 2023 | 95 | 111 | $179,000 | $53,151 | 29.7% |
| 17312 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | Office | 2023 | 53 | 76 | $48,000 | $27,780 | 57.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 253 | 364 | $70,800 | $25,706 | 36.3% |
| 17313 | Removal and microscopic exam of growth of trunk, arms, or legs, 1-5 tissue blocks | Office | 2023 | 41 | 45 | $38,850 | $25,034 | 64.4% |
| 14040 | Repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet by transferring skin, 10.0 sq cm or less | Office | 2023 | 25 | 28 | $35,200 | $18,253 | 51.9% |
| 14060 | Repair of wound of eyelids, nose, ears, or lips by transferring skin, 10.0 sq cm or less | Office | 2023 | 24 | 25 | $52,200 | $16,612 | 31.8% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 112 | 134 | $46,775 | $10,394 | 22.2% |
| 13121 | Complicated repair of wound of scalp, arms, or legs, 2.6-7.5 cm | Office | 2023 | 29 | 33 | $55,650 | $7,741 | 13.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 89 | 89 | $22,250 | $6,815 | 30.6% |
| 17314 | Removal and microscopic exam of growth of trunk, arms, or legs, each additional stage, 1-5 tissue blocks | Office | 2023 | 17 | 18 | $11,550 | $6,402 | 55.4% |
| 13132 | Complicated repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet, 2.6-7.5 cm | Office | 2023 | 19 | 20 | $17,000 | $5,686 | 33.4% |
| 13101 | Complicated repair of wound of trunk, 2.6-7.5 cm | Office | 2023 | 21 | 21 | $19,200 | $4,666 | 24.3% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 66 | 90 | $26,650 | $4,448 | 16.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 68 | 87 | $13,050 | $3,618 | 27.7% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 37 | 74 | $12,800 | $3,388 | 26.5% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 16 | 25 | $9,375 | $3,222 | 34.4% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 49 | 337 | $16,730 | $1,997 | 11.9% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 14 | 15 | $5,250 | $1,430 | 27.2% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 20 | 20 | $4,500 | $1,085 | 24.1% |
| 17311 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | Office | 2022 | 89 | 105 | $182,350 | $55,837 | 30.6% |
| 17313 | Removal and microscopic exam of growth of trunk, arms, or legs, 1-5 tissue blocks | Office | 2022 | 37 | 44 | $37,550 | $24,940 | 66.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 216 | 322 | $62,655 | $23,322 | 37.2% |
| 17312 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | Office | 2022 | 41 | 60 | $38,500 | $22,631 | 58.8% |
| 14040 | Repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet by transferring skin, 10.0 sq cm or less | Office | 2022 | 21 | 21 | $25,100 | $14,291 | 56.9% |
| 14060 | Repair of wound of eyelids, nose, ears, or lips by transferring skin, 10.0 sq cm or less | Office | 2022 | 18 | 19 | $40,950 | $13,179 | 32.2% |
About Dr. David Goldberg, M.D
Dr. David Goldberg, M.D is a MOHS-Micrographic Surgery healthcare provider based in Hackensack, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1528001583.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Goldberg, M.D has received a total of $1.4M in payments from pharmaceutical and medical device companies, with $172,911 received in 2024. These payments were reported across 434 transactions from 49 companies. The most common payment nature is "Grant" ($622,035).
As a Medicare-enrolled provider, Goldberg has provided services to 4,411 Medicare beneficiaries, totaling 6,798 services with total Medicare billing of $959,196. Data is available for 4 years (2020–2023), covering 84 distinct procedure/service records.
Ad
Practice Information
- Specialty MOHS-Micrographic Surgery
- Other Specialties MOHS-Micrographic Surgery, MOHS-Micrographic Surgery
- Location Hackensack, NJ
- Active Since 06/14/2006
- Last Updated 09/20/2019
- Taxonomy Code 207ND0101X
- Entity Type Individual
- NPI Number 1528001583
Products in Payments
- ACZONE (Drug) $38,541
- PHAROS laser system (Device) $15,116
- LIBTAYO (Biological) $13,507
- NO PRODUCT DISCUSSED (Drug) $9,431
- YCANTH (Drug) $7,767
- BF-RhodoLED (Device) $7,500
- SKYRIZI (Biological) $7,500
- RHOFADE (Drug) $4,462
- DYSPORT (Drug) $3,515
- BOTOX (Biological) $3,207
- Ameluz (Drug) $3,073
- QBREXZA (Drug) $2,986
- SEYSARA (Drug) $2,565
- Xeomin (Biological) $1,626
- AMELUZ (Drug) $1,579
- WYNZORA (Drug) $1,500
- XEOMIN (Biological) $1,445
- SOOLANTRA (Drug) $1,345
- Puraply (Medical Supply) $421.38
- EUCRISA (Drug) $225.82
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.